Clinical Trials Sponsored by Capstone Therapeutics

Total 6256 results

Capstone Therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars

Scar Prevention | Scar Reduction

United States
Capstone Therapeutics

Completed

A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients

Scar Prevention | Scar Reduction

United States
Capstone Therapeutics

Terminated

A Study to Evaluate the Safety and Effectiveness of Different Doses of Chrysalin in Adults Who Have a Broken Wrist

Radius Fracture

United States
Capstone Therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

Scar Prevention | Scar Reduction

United States
CStone Pharmaceuticals

Active, not recruiting

A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Stage III

China
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)

Extranodal Natural Killer/T-Cell Lymphoma

United States, China
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
CStone Pharmaceuticals

Completed

Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients

Relapsed Small Cell Lung Cancer

China
CStone Pharmaceuticals

Completed

A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation

Relapsed or Refractory Acute Myeloid Leukemia

China
CStone Pharmaceuticals

Completed

A Study of CS1002 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

Hong Kong, Australia
CStone Pharmaceuticals

Completed

A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

China
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Hodgkin Lymphoma

China
CStone Pharmaceuticals

Completed

A Study of CS3005 in Advanced Solid Tumors

Advanced Solid Tumor

Australia
CStone Pharmaceuticals

Completed

A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
CStone Pharmaceuticals

Completed

A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Solid Tumor, Adult

Australia
CStone Pharmaceuticals

Not yet recruiting

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Extranodal NK/T-cell Lymphoma
CStone Pharmaceuticals

Recruiting

Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World

Gastrointestinal Stromal Tumors

China
CStone Pharmaceuticals

Recruiting

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Advanced Solid Tumor | Advanced Lymphoma

China, Australia, United States
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
CStone Pharmaceuticals

Active, not recruiting

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Spain, China, United States, Poland, Italy, Taiwan
CStone Pharmaceuticals

Active, not recruiting

A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

China
CStone Pharmaceuticals

Completed

A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

Advanced Cancer

China
CStone Pharmaceuticals

Completed

A Study of CS1003 in Subjects With Advanced Solid Tumors

Advanced Cancer

Australia
CStone Pharmaceuticals

Terminated

A Study of CS3002 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia
CStone Pharmaceuticals

Completed

Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
CStone Pharmaceuticals
Pfizer

Active, not recruiting

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

China
CStone Pharmaceuticals
Bayer

Completed

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Advanced Refractory Solid Tumors

Australia
CorStone
David and Lucile Packard Foundation

Active, not recruiting

Youth First: A Longitudinal Impact Evaluation

Mental Health Wellness 1 | Resilience, Psychological

India
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
CStone Pharmaceuticals
Blueprint Medicines Corporation

Completed

A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors

China
CStone Pharmaceuticals
Blueprint Medicines Corporation

Completed

A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
CStone Pharmaceuticals

Recruiting

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Circassia Limited
Adiga Life Sciences, Inc.; Topstone Research

Completed

An Optional Investigation of Biomarkers of Efficacy

Rhinoconjunctivitis

Canada
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Clear Cell Renal Cell Carcinoma | Pancreatic Adenocarcinoma | Cervical Carcinoma | Malignant Pleural Mesothelioma | Esophageal Carcinoma

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

T Cell Lymphoma

United States, Australia, Canada
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

B-cell Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Adult B Cell ALL

United States, Spain, Canada, France, Germany, Australia
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Celsus Therapeutics PLC

Terminated

Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (C012013)

Atopic Dermatitis

Israel
Eikon Therapeutics
Impact Therapeutics, Inc.

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Australia, United States
APRINOIA Therapeutics, LLC

Active, not recruiting

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

Alzheimer Disease | Tauopathies | Healthy Volunteers

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Renal Cell Carcinoma

United States, Australia, Canada, Netherlands
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Large B-cell Lymphoma | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

United States
CRISPR Therapeutics AG

Enrolling by invitation

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Hematologic Malignancy | Solid Malignancy

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada
APRINOIA Therapeutics, LLC

Active, not recruiting

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

Healthy Volunteers | Alzheimer's Disease | Mild Cognitive Impairment Due to Alzheimer's Disease

United States
CRISPR Therapeutics AG
ViaCyte

Recruiting

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

Glucose Metabolism Disorders | Immune System Diseases | Autoimmune Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Mellitus, Type 1 | Metabolic Disease

Canada
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China

Clinical Trials Sponsored by Capstone Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations